|
1
|
Peralta-Leal A, Rodríguez-Vargas JM,
Aguilar-Quesada R, Rodríguez MI, Linares JL, de Almodóvar MR and
Oliver FJ: PARP inhibitors: new partners in the therapy of cancer
and inflammatory diseases. Free Radic Biol Med. 47:13–26. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rouleau M, Patel A, Hendzel MJ, Kaufmann
SH and Poirier GG: PARP inhibition: PARP1 and beyond. Nat Rev
Cancer. 10:293–301. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Helleday T, Petermann E, Lundin C, Hodgson
B and Sharma RA: DNA repair pathways as targets for cancer therapy.
Nat Rev Cancer. 8:193–204. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Graziani G and Szabó C: Clinical
perspectives of PARP inhibitors. Pharmacol Res. 52:109–118. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee JM, Ledermann JA and Kohn EC: PARP
Inhibitors for BRCA1/2 mutation-associated and BRCA-like
malignancies. Ann Oncol. 25:32–40. 2014. View Article : Google Scholar :
|
|
6
|
Ashworth A: A synthetic lethal therapeutic
approach: poly(ADP) ribose polymerase inhibitors for the treatment
of cancers deficient in DNA double-strand break repair. J Clin
Oncol. 26:3785–3790. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
No authors listed. Olaparib enters phase
III clinical testing. Cancer Discovery. 3:12102013. View Article : Google Scholar
|
|
8
|
Rottenberg S, Jaspers JE, Kersbergen A, et
al: High sensitivity of BRCA1-deficient mammary tumors to the PARP
inhibitor AZD2281 alone and in combination with platinum drugs.
Proc Natl Acad Sci USA. 105:17079–17084. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pal T, Permuth-Wey J, Betts JA, et al:
BRCA1 and BRCA2 mutations account for a large proportion of ovarian
carcinoma cases. Cancer. 104:2807–2816. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Menear KA, Adcock C, Boulter R, et al:
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one:
a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J
Med Chem. 51:6581–6591. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weston VJ, Oldreive CE, Skowronska A, et
al: The PARP inhibitor olaparib induces significant killing of
ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood.
116:4578–4587. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thomas HD, Calabrese CR, Batey MA, et al:
Preclinical selection of a novel poly(ADP-ribose) polymerase
inhibitor for clinical trial. Mol Cancer Ther. 6:945–956. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Drew Y, Mulligan EA, Vong WT, et al:
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor
AG014699 in human cancers with mutated or methylated BRCA1 or
BRCA2. J Natl Cancer Inst. 103:334–346. 2011. View Article : Google Scholar
|
|
14
|
Mah LJ, El-Osta A and Karagiannis TC:
gammaH2AX: a sensitive molecular marker of DNA damage and repair.
Leukemia. 24:679–686. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kepp O, Galluzzi L, Lipinski M, Yuan J and
Kroemer G: Cell death assays for drug discovery. Nat Rev Drug
Discov. 10:221–237. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li X, Zhang BG and Jia LL: Establishment
of transplantable human pancreatic carcinoma model in nude mice and
study of its biological characteristics. J China Med Univ.
22:161–163. 1993.(In Chinese).
|
|
17
|
Min A, Im SA, Yoon YK, et al:
RAD51C-deficient cancer cells are highly sensitive to the PARP
inhibitor olaparib. Mol Cancer Ther. 12:865–877. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Issaeva N, Thomas HD, Djureinovic T, et
al: 6-thioguanine selectively kills BRCA2-defective tumors and
overcomes PARP inhibitor resistance. Cancer Res. 70:6268–6276.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mendes-Pereira AM, Martin SA, Brough R, et
al: Synthetic lethal targeting of PTEN mutant cells with PARP
inhibitors. EMBO Mol Med. 1:315–322. 2009. View Article : Google Scholar
|
|
20
|
McCabe N, Turner NC, Lord CJ, et al:
Deficiency in the repair of DNA damage by homologous recombination
and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer
Res. 66:8109–8115. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lord CJ, McDonald S, Swift S, Turner NC
and Ashworth A: A high-throughput RNA interference screen for DNA
repair determinants of PARP inhibitor sensitivity. DNA Repair
(Amst). 7:2010–2019. 2008. View Article : Google Scholar
|
|
22
|
Bajrami I, Frankum JR, Konde A, et al:
Genome-wide profiling of genetic synthetic lethality identifies
CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Cancer Res. 74:287–297. 2014. View Article : Google Scholar
|
|
23
|
Farmer H, McCabe N, Lord CJ, et al:
Targeting the DNA repair defect in BRCA mutant cells as a
therapeutic strategy. Nature. 434:917–921. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Murai J, Huang SY, Das BB, et al: Trapping
of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res.
72:5588–5599. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hermann PC, Huber SL, Herrler T, et al:
Distinct populations of cancer stem cells determine tumor growth
and metastatic activity in human pancreatic cancer. Cell Stem Cell.
1:313–323. 2007. View Article : Google Scholar
|
|
26
|
Güngör C, Hofmann BT, Wolters-Eisfeld G
and Bockhorn M: Pancreatic cancer. Brit J Pharmacol. 171:849–858.
2014. View Article : Google Scholar
|
|
27
|
Kurian AW: BRCA1 and BRCA2 mutations
across race and ethnicity: distribution and clinical implications.
Curr Opin Obstet Gynecol. 22:72–78. 2010. View Article : Google Scholar
|
|
28
|
Thirthagiri E, Lee SY, Kang P, et al:
Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models
in a typical Asian country (Malaysia) with a relatively low
incidence of breast cancer. Breast Cancer Res. 10:R592008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Untawale S, Odegaard AO, Koh WP, Jin AZ,
Yuan JM and Anderson KE: Body mass index and risk of pancreatic
cancer in a Chinese population. PLoS One. 9:e851492014. View Article : Google Scholar : PubMed/NCBI
|
